由于产量未达标，只有1/11的印度人接种了Covaxin疫苗

Only 1 in 11 gets Covaxn as Bharat Biotech falls short of production targets

由于巴拉特生物技术公司的产量未能达到目标，只有1 / 11的人接种了Covaxn疫苗

MUMBAI: Homegrown Covaxn was to play a major role in vaccination against Covid-19. But eight months after the vaccination drive began, only one in 11 Indians has managed to get the first indigenous vaccine. Bharat Biotech, which manufactures it, has failed to ramp up production at the pace it had envisaged.

孟买：印度国产Covaxn将在新冠疫苗接种中发挥重要作用。但在疫苗接种运动开始8个月后，只有1 / 11的印度人接种的第一针疫苗是这款本土疫苗。该疫苗的制造商巴拉特生物技术公司(Bharat Biotech)未能按照计划提高产量。

Stymied by shortages of drug substance and filling capacity, the Hyderabad-based company has repeatedly fallen short of the target it had set for itself. In between, it also saw a batch of its vaccine face quality issues.

由于原料药的短租和灌装能力的不足，这家总部位于海德拉巴的公司屡次未能达到为自己设定的目标。在此期间，该公司还发现其一批疫苗存在质量问题。

Its CMD Krishna Ella recently said the company would supply 5.5 crore doses from October, from the exsting 3.5 crore doses-- substantially lower than the initially-expected 10 crore.

该公司的CMD Krishna Ella最近表示，该公司将从10月份开始供应5500万剂疫苗，而现有的供应剂量为3500万剂，大大低于最初预期的1亿剂。

In May, in an affidavit before the Supreme Court, the Centre had projected that 55 crore doses of Covaxn -- or an average of 10 crore monthly doses, would be available during August-December. A month later, this was slashed by 20% to eight crore. However, the monthly capacity for August and September is far lower.

今年5月，印度政府在最高法院的一份宣誓书中预测，8月至12月期间将提供5.5亿剂Covaxn疫苗，平均每月1亿剂。一个月后，这一数字下降了20%，降到8000万。然而，8月和9月的月度产能要低得多。

This puts a question mark on the company's ability to boost production and supply the numbers as per its commitment. Interestingly, there has been a huge mismatch in the capacity projected both by the company and government, and what has been supplied so far.

这给该公司按照承诺提高产量和供应能力打上了问号。有趣的是，该公司和政府预测的产能和目前供应的产能存在巨大的差距。

Queries sent by TOI to the company on September 24 seeking details of its capacity remained unanswered.

9月24日，《印度时报》向该公司发出询问，寻求其产能的细节，但未收到回复。

Concerns around the supply of Covaxn have persisted over the last few months, with Serum Institute-manufactured Covishield accounting for over 90% of all vaccines administered. About one crore daily doses are required to vaccinate the entire 94 crore eligible population by December 31.

在过去几个月里，对Covaxn疫苗供应的担忧一直存在，血清研究所生产的Covishield占所有接种疫苗的90%以上。要在12月31日之前为全部9.4亿可接种人口接种疫苗，每天需要大约完成1000万剂疫苗的接种。

以下是印度时报读者的评论：译者：Jessica.Wu

Vikas B

85 crore people already vaccinated. Great effort by government best in world.

8.5亿印度人已经接种了疫苗。印度政府是做得最好的。

Ravindra Bhave

Rather than blaming BJP, find out out who is stop them from geting raw materials and fire the manager

与其指责印度人民党，不如找出是谁阻止他们获得原料的，然后解雇负责人

Pranav Pathrikar

Estimated Vaccine numbers were exaggerated by Bjpee to cover up for their mistake of sending abroad many vaccines.

预计的疫苗产量被人民党夸大了，为了掩盖他们把疫苗出口到国外的错误。

Scl Premi

Impose heavy penalties on the highly inefficient Bharat Biotech for inordinate delay in a project of national and global importance to beat the pandemic.

对效率极低的印度巴拉特生物技术公司处以重罚，国内和全球抗击疫情，该公司过度拖延。

Tanmoy Kar

Thanks to the increase in production of Serum Institute we somehow survived the possible third wave.

多亏了血清研究所增加产量，我们才能挺过可能爆发的第三波疫情。

Vikas

First focus should be to get it approved by WHO.... Once done, only then this should be administered... We dont even know why it is not getting approved.... if quality is not up to the mark then lets focus on improving it.... if it is due to pharma politics by US, diplometic channels should be used.

重点应该是获得世卫组织的批准....获批了才能接种……我们甚至不知道为什么它没有获得批准....如果质量没有达到标准，那就努力改进....如果是美国从中作梗，那就应该利用外交渠道解决。

sonjusen

It was propped up by BJP.

它得到了人民党的支持。

Saikumar C Krishna

What happened to the world health bodies approval of Covaxn? it was supposed to get approved by September

世界卫生组织为什么不批准Covaxn疫苗？应该在9月获批的

Venbas2 Venbas2

I had my CoVaxn shots in April and can say with high confidence that CoVaxn is far superior than international vaccines including the UK AstraZeneca based Covishield.

我在4月份接种了Covaxn疫苗，我可以很有信心地说，Covaxn远远优于外国疫苗，也优于英国阿斯利康公司的Covishield。

Unmaivilambi

what is the use in bum up the production of a vaccince that is yet to get WHO approval?

增产一种尚未获得世卫组织批准的疫苗有什么用?

Amitabh Singh

poor showing by Bharat biotech

巴拉特生物技术表现不佳

Asok Datta

Failure of BJP to assess the correct capability of BBT to meet the target production- their efficiency was unduly bloated

印度人民党评估的巴拉特技术公司的产能不准——他们的效率被过度夸大了

Puneet Mehra

I am hearing that Covaxn is a dud vaccine. I have seen how it was being administered. It was kept in 45 degrees temperature for 30 mins before injecting in people.

我听说Covaxn是无效疫苗。我看到他们是怎么注射的，在注射之前，在45度的温度下保存了30分钟。

Whereisindiaheading

All figures from BJP is wrong!!

人民党给出的所有数据都是错的！

Ankush

but feku is eager to export them

莫迪还想出口

kSingh

Everything about this company is unethical.

这公司不道德

Agnelo Dsa

crooked company. was helped by the goverment of India in develo the vaccine.

claims were made that this vaccine would cost less than a bottle of water. what is the price of this vaccine today?

why is there a shortage?

骗子公司。在开发疫苗方面得到了印度政府的帮助。

据说这种疫苗比一瓶水还便宜。现在这种疫苗的价格是多少？为什么会出现短缺？

Bks

Poor management by Biotech.

巴拉特生物技术公司管理不善。

Covaxn was promoted by Modi under favours to BJP. That company was never going to be able to produce sufficient doses. Even the efficacy is fake. The health of crores of Indians was compromised by this megalomaniac.

在印度人民党的支持下，莫迪提拔了Covaxn。那家公司永远无法生产出足够的剂量，甚至药效都是假的。亿万印度人的健康被这个自大狂所损害。

Gary S

When will it get WHO recognised?

这疫苗什么时候能获得世卫组织的认可？